Cabozantinib
Drug
Exelixis Inc.
Total Payments
$39.9M
Transactions
4,266
Doctors
33
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $20.3M | 2,451 | 19 |
| 2019 | $11.6M | 979 | 15 |
| 2018 | $4.5M | 472 | 8 |
| 2017 | $3.5M | 364 | 7 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $36.5M | 4,006 | 91.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2.4M | 82 | 6.0% |
| Consulting Fee | $810,533 | 110 | 2.0% |
| Grant | $75,000 | 6 | 0.2% |
| Royalty or License | $37,600 | 1 | 0.1% |
| Space rental or facility fees (teaching hospital only) | $28,607 | 15 | 0.1% |
| Honoraria | $6,013 | 1 | 0.0% |
| Charitable Contribution | $5,000 | 1 | 0.0% |
| Travel and Lodging | $2,350 | 14 | 0.0% |
| Food and Beverage | $1,431 | 30 | 0.0% |
Payments by Type
Research
$36.5M
4,006 transactions
General
$3.4M
260 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | Exelixis Inc. | $18.5M | 0 |
| A Randomized, Double-Blind, Controlled Phase 3 Study of Cabozantinib in Combination with Nivolumab and Ipilimumab versus Nivolumab and Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma of Intermediate or Poor Ris | Exelixis Inc. | $2.9M | 0 |
| A Randomized, Controlled Phase 3 Study of Cabozantinib XL184) in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | Exelixis Inc. | $2.1M | 0 |
| A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib XL184) in Subjects with Radioiodine Refractory Differentiated Thyroid Cancer who have Progressed after Prior VEGFR-Targeted Therapy | Exelixis Inc. | $1.2M | 0 |
| A Single-arm, two-stage, Phase ll Study of Cabozantinib in patients with refractory metastatic colorectal cancer | Exelixis Inc. | $1.1M | 0 |
| A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Exelixis Inc. | $896,012 | 0 |
| A Phase 3, Randomized, Controlled Study of Cabozantinib XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy | Exelixis Inc. | $765,839 | 0 |
| A Randomized, Controlled Phase 3 Study of Cabozantinib XL184 in Combination with Atezolizumab versus Sorafenib in Subjects with Advanced Hepatocellular Carcinoma Who Have Not Received Previous Systemic Anticancer Therapy | Exelixis Inc. | $603,062 | 0 |
| METEOR translational studies | Exelixis Inc. | $600,643 | 0 |
| CABOSUN II Cabozantinib versus Sunitinib for Metastatic Variant Histology Renal Cell Carcinoma | Exelixis Inc. | $393,426 | 0 |
| A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of Cabozantinib XL184 in Subjects with Radioiodine Refractory Differentiated Thyroid Cancer who have Progressed after Prior VEGFR-Targeted Therapy | Exelixis Inc. | $345,695 | 0 |
| An open-label, single-arm, two-stage phase II study investigating cabozantinib in patients with refractory metastatic colorectal cancer | Exelixis Inc. | $329,000 | 0 |
| A Phase 1b Dose Escalation Study of Cabozantinib XL184 Administered Alone or in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors | Exelixis Inc. | $315,861 | 0 |
| A phase 2 Open-label Study of cabozantinib combined with nivolumab CaboNivo in Subjects with Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Exelixis Inc. | $282,953 | 0 |
| A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib XL184 vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib | Exelixis Inc. | $260,034 | 0 |
| A Phase II Study of Nivolumab in Combination with Cabozantinib for Metastatic Triple-Negative Breast Cancer | Exelixis Inc. | $250,417 | 0 |
| Using Cabozantinib to Enhance the Efficacy of Immunotherapy in Hepatocellular Carcinomo and Metastatic Breast Cancer Models | Exelixis Inc. | $240,042 | 0 |
| A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes ROS1 or NTRK Fusions or Increased MET or AXL Activity | Exelixis Inc. | $218,424 | 0 |
| A phase 2 Open-label Study of cabozantinib combined with nivolumab CaboNivo) in Subjects with Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma | Exelixis Inc. | $209,059 | 0 |
| Cabozantinib plus Pembrolizumab - Single-arm, Non-Randomized, Phase II Study of First-line Therapy for Cisplatin CDDP)-ineligible Advanced Urothelial Carcinoma | Exelixis Inc. | $208,141 | 0 |
Top Doctors Receiving Payments for Cabozantinib
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Winter Park, CO | $39.3M | 4,148 |
| , M.D | Medical Oncology | San Francisco, CA | $420,000 | 14 |
| , MD | Hematology & Oncology | Cleveland, OH | $35,905 | 8 |
| , M.D | Internal Medicine | Palo Alto, CA | $34,940 | 15 |
| , M.D | Hematology & Oncology | Scottsdale, AZ | $12,400 | 6 |
| , MD | Medical Oncology | Evanston, IL | $9,700 | 9 |
| , MD | Endocrinology, Diabetes & Metabolism | Cleveland, OH | $8,225 | 4 |
| , M.D | Medical Oncology | Boston, MA | $6,013 | 1 |
| , M.D | Hematology & Oncology | Pittsburgh, PA | $5,801 | 7 |
| , M.D | Gastroenterology | Stanford, CA | $5,400 | 3 |
| , M.D | Hepatology | Dallas, TX | $5,184 | 3 |
| , MD | Internal Medicine | Charlotte, NC | $4,678 | 3 |
| , M.D | Hematology & Oncology | Los Angeles, CA | $2,765 | 1 |
| , MD | Internal Medicine | Boston, MA | $2,656 | 6 |
| William Ferri | Hematology & Oncology | Beaver, PA | $2,227 | 3 |
| , MD | Hematology & Oncology | Plano, TX | $2,227 | 3 |
| , M.D | Hematology & Oncology | Chicago, IL | $2,227 | 3 |
| Amer Khouri | — | Kennewick, WA | $2,227 | 3 |
| , M.D | Specialist | San Francisco, CA | $2,100 | 1 |
| , MD | Hematology & Oncology | Wexford, PA | $2,027 | 3 |
| , MD | Hematology & Oncology | Redondo Beach, CA | $1,747 | 3 |
| Vikram Gorantla | Hematology & Oncology | Pittsburgh, PA | $1,523 | 2 |
| , M.D | Gynecologic Oncology | Oklahoma City, OK | $202.44 | 2 |
| , MD | Internal Medicine | Salt Lake City, UT | $123.92 | 3 |
| , M.D | Hematology & Oncology | Portland, OR | $66.73 | 1 |
Ad
Manufacturing Companies
- Exelixis Inc. $39.9M
Product Information
- Type Drug
- Total Payments $39.9M
- Total Doctors 33
- Transactions 4,266
About Cabozantinib
Cabozantinib is a drug associated with $39.9M in payments to 33 healthcare providers, recorded across 4,266 transactions in the CMS Open Payments database. The primary manufacturer is Exelixis Inc..
Payment data is available from 2017 to 2020. In 2020, $20.3M was paid across 2,451 transactions to 19 doctors.
The most common payment nature for Cabozantinib is "Unspecified" ($36.5M, 91.6% of total).
Cabozantinib is associated with 20 research studies, including "Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors" ($18.5M).